key: cord-0897382-0h3yv2m4 authors: Phillips, Christopher J.; Schoen, Robert E. title: Screening For Colorectal Cancer in the Age of Simulation Models:A Historical Lens date: 2020-07-16 journal: Gastroenterology DOI: 10.1053/j.gastro.2020.07.010 sha: 8c826b7b81865439d0c9c0217c81a4e8d4857927 doc_id: 897382 cord_uid: 0h3yv2m4 nan In late March, The Washington Post, citing unnamed officials, quoted Dr. Anthony S. Fauci's response to the demands of modeling the novel coronavirus epidemic: "I've looked at all the models. I've spent a lot of time on the models. They don't tell you anything. You can't really rely upon models." 1 In this commentary, we report on the historical evolution of simulation modeling as applied to screening for CRC. We highlight how simulation modeling has come to be regarded by some as equivalent to evidence based data, but we caution against overreach by relying too heavily on modeling relative to empirical testing. Computer simulation models sit uncomfortably alongside evidence provided by controlled observational studies and formal randomized trials. Simulations are at once experimental-researchers can adjust parameters and observe different outcomes-and yet also fundamentally non-empirical, in that the parameters, inputs, and assumptions need not have strong empirical bases of support. According to Douglas Owens of Stanford University and the USPSTF, the introduction of simulation modeling into colorectal cancer screening recommendations helped address questions that clinical trials had left unanswered. 7 But as Eric Winsberg's survey of the rise of computer simulation has noted, "It is a mistake to think of simulations simply as tools for unlocking hidden empirical content." 8 Simulations do not produce empirical evidence; they enable the creation of "present futures" or alternative visions of the future to help decision making in the present. 9 As recently as 1996, however, simulation models were not used at all in screening recommendations. The rapid rise in their importance over the following two decades, and their central role in shaping current screening recommendations, should occasion reflection about how and why simulation models have become an influential tool for medical decision making. Though the introduction of electronic computers and algorithms into medicine broadly dates back to the 1950s, the idea of simulating the effects of screening with computers arose only in the early 1970s. 10 [12] [13] During the 1980s, computer simulations of screening regimens proliferated as researchers sought to understand their potential benefits and costs. [14] [15] [16] Until the twenty-first century, however, computer simulations were not seen as providing evidence definitive enough to shape screening recommendations. Randomized controlled trials (RCTs) continued to provide the highest level of empirical evidence for the USPSTF and the Canadian Task Force on Preventive Health Care. 17 The 1996 Guide to Clinical Preventive Services of the USPSTF did not rely on even established simulation models and two years later USPSTF representatives advocating for the use of models still acknowledged "important obstacles" because models were "invariably complex and involve numerous assumptions and subjective judgments." [18] [19] A major turning point was the development of the Cancer Intervention and Simulated Population model for Incidence and Natural history). Models for CRC screening were often based on those designed for breast and cervical cancer, but emerged later because empirical studies on the effects of colorectal cancer screening arrived later. The first colorectal cancer models were created in the 1990s, [20] [21] incorporating the first randomized controlled studies of CRC screening. [22] [23] [24] [25] The resulting simulation models within the CISNET group are similar in many regards: all are stochastic microsimulation models (meaning that instead of cohorts they model an individual's probabilistic transition between disease states) and all take into account the natural history of colorectal cancer as well as Surveillance, Epidemiology, and End Results (SEER) incidence and mortality data. In preparation for its 2008 recommendations on colorectal cancer screening, the USPSTF augmented their systematic evidence review for the first time with models provided by CISNET researchers, prompting praise for the use of state-of-the-art technology but also concern that modelers had made some "surprising choices," including not quality-adjusting estimates of benefits or accounting for patient and institutional costs of adherence. 26 By 2016, the USPSTF's CRC recommendations relied heavily on CISNET researchers to provide information on the starting and stopping ages, as well as recommended intervals for screening methods. In particular, CISNET researchers modeled the experience of 40-year old individuals with no previous cancer diagnosis, and aggregated those experiences over an entire hypothetical cohort to measure both the benefit (in life-years gained (LYG)) and the cost (in number of lifetime colonoscopies required) of screening. Effectiveness was defined by an "efficient frontier," highlighting the strategies that provided the "largest incremental increase in LYG per additional colonoscopy performed." 27 They concluded "the strategies of colonoscopy every 10 years, annual FIT (fecal immunochemical testing), SIG (flexible sigmoidoscopy) every 10 years with annual FIT, and CTC (computerized tomographic colonography) every 5 years performed from ages 50 to 75 years provided similar LYG and a comparable balance of benefit and screening burden." 28 All three models predicted that starting screening at age 45 would result in an increase in life years gained but the USPSTF rejected recommending earlier initiation dates. They reasoned that the increase in life years gained relative to the burden of increased colonoscopy exams was small. Combining an earlier starting age with an extension of the subsequent screening interval from every 10 to every 15 years would have maintained a similar estimate of required lifetime colonoscopies but one of the three models (MISCAN-Colon) predicted this solution would cause a loss in LYG. In the end, the USPSTF considered these findings and concluded that "the evidence best supports a starting age of 50 years for the general population, noting the modest increase in life-years gained by starting screening earlier, the discordant findings across models for extending the screening interval when the age at which to begin screening is lowered, and the lack of empirical evidence in younger populations." 28 The American Cancer Society's review two years later addressed the question of initiation age by homing in on the discordant findings across models. In particular, they noted the apparent outlier, the MISCAN-Colon simulation model, would have agreed with the other two about the benefit of starting screening at age 45 if it had incorporated new information on the increased incidence of colorectal cancer in younger people. 29 All three CISNET models had used SEER incidence rates taken from 1975-1979 (providing an incidence rate prior to the institution of appreciable screening activity, hence more reflective of the underlying natural history). The ACS research team used MISCAN-Colon to simulate "a cohort of adults aged 40 years in 2015, and assumed that this cohort had a 1.591-fold increased CRC incidence across all ages compared with the original model." 30 The incidence multiplier was derived from comparing SEER data from 1975 with more recent incidence rates. Re-running the MISCAN-Colon model with updated assumptions resulted in the ACS Guideline Development Group providing a qualified recommendation that screening begin at 45, while maintaining initiation at 50 as a strong recommendation. [31] [32] In this instance, the use of a simulation model for CRC screening recommendations engendered controversy rather than resolved questions. Though there was indeed new epidemiological evidence on colorectal cancer incidence published between 2016 and 2018 29 there were no new empirical studies about the effects of earlier screening. In fact, as the ACS group acknowledged, there has never been any substantial research on the effects of starting screening before age 50 for colorectal cancer. 32 While the model predicts benefits in earlier detection of CRC, a number of unintended consequences could potentially follow 6 primary of which is the diversion of resources away from higher risk populations for whom the relative benefit of screening is substantially greater. 33 Moreover, the agreement or disagreement of models is not a straightforward measure of the strength or weakness of evidence. It is difficult to know whether differences in predictions are due to differences in model design or model inputs. 34 Two models which have been accurately validated using existing studies may have quite different predictions about future outcomes. A 2016 study by CISNET-CRC modelers, for example, noted that the essential but unobservable process of transition from benign adenoma to malignant tumor, or "dwell-time," is simulated by all the models but such a value is an output rather than input or assumption. As a result, even if models are carefully calibrated to match existing data, information about how sensitive predictions are to different dwell-time distributions, for example, remains unknown. 35 Given the expense of trials and the difficulty of combining multiple parameters simultaneously, such as age of initiation, screening interval, and preferred modalitymodeling may indeed be an essential component for decision making. The ease of modeling compared to large-scale clinical trials as well as the ability of models to combine evidence from many different sources also favors their use. Models have significant limitations however, from their imposition of assumptions about the natural history of disease, the screening process, and the behavior of individuals, to the possibility of producing results with misleading levels of precision. Most importantly, no matter how elaborate the design of the "virtual laboratory" created by a model 36 or the quality of the "experiments" within, empirical studies remain essential. As has become abundantly clear in the case of statins 37 and hormone replacement therapy 38 in the absence of large and unexpected effects, only randomized controlled trials of adequate size performed in applicable settings can provide reliable information about an intervention's effectiveness. As Dr. Fauci said recently, "All models are just models. When you get new data, you change them." 39 New epidemiological data on incidence rates can certainly justify updating a model's assumptions, which then might lead the model to make different predictions about the effects of screening, but without formal randomized trials of the new intervention, we have no new empirical information about effectiveness. Computer simulations have subtly expanded what counts as "evidence-based" medicine. Balancing reliance on models with careful assessment of the systematic and empirical evidence is the core responsibility of organizations developing and delivering prescriptions for public policy. Careful deliberation is required to avoid over reliance on modeling. Models are no substitute for "real-world data" 40 and their conclusions remain bound by the availability of rigorous empirical studies. Experts and Trump's advisers doubt White House's 240,000 coronavirus deaths estimate Evolution of mathematical models of epidemics From colorectal cancer screening guidelines to headlines: Beware! When should guidelines change? A clarion call for evidence regarding the benefits and risks of screening for colorectal cancer at earlier ages Lowering the starting age for colorectal cancer screening to 45 years: who will come...and should they? Potential intended and unintended consequences of recommending initiation of colorectal cancer screening at age 45 years Bauchner: screening for colorectal cancer Science in the age of computer simulation Imagined futures: fictional expectations and capitalist dynamics Biomedical computing: digitizing life in the united states A Simulation System for Screening Procedures The paradox of authority -transformation of the USPSTF under the Affordable Care Act Background and Objectives of the U.S. Preventive Services Task Force The MISCAN simulation program for the evaluation of screening for disease A computer simulation model for the practical planning of cervical cancer screening programmes Optimising the age, number of tests, and test interval for cervical screening in Canada Statistical models for cancer screening Broadening the evidence base for evidence-based guidelines: a research agenda based on the work of the U.S. Preventive Services Task Force US Preventive Services Task Force. Guide to Preventive Services Screening for colorectal cancer The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening Randomised controlled trial of faecaloccult-blood screening for colorectal cancer Randomised study of screening for colorectal cancer with faecal-occult-blood test Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study The effect of fecal occult-blood screening on the incidence of colorectal cancer Screening guidelines for colorectal cancer: a twice-told tale Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US Preventive Services Task Force US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force Recommendation Statement Colorectal cancer incidence patterns in the United States, 1974-2013 The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: microsimulation analysis I to inform the American Cancer Society Colorectal Cancer Screening Guideline Optimizing colorectal cancer screening by race and sex: microsimulation analysis II to inform the American Cancer Society Colorectal Cancer Screening Guideline Colorectal cancer screening for average-risk adults Cost-effectiveness and national effects of initiating colorectal cancer screening for average-risk persons at age 45 years instead of 50 years Diversity of model approaches for breast cancer screening: a review of model assumptions by The Cancer Intervention and Surveillance Network (CISNET) Breast Cancer Groups Validation of models used to inform colorectal cancer screening guidelines: accuracy and implications Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) breast cancer models Interpretation of the evidence for the efficacy and safety of statin therapy When are randomised trials unnecessary? Picking signal from noise The Coronavirus in America: The Year Ahead. The New York Times Real-world evidence and real-world data for evaluating drug safety and effectiveness